United Therapeutics
United Therapeutics Corporation is an American biotechnology company focused on the development and commercialization of novel pharmaceutical therapies and organ manufacturing technologies. The company's operational portfolio concentrates heavily on severe, chronic cardiovascular conditions, primarily pulmonary arterial hypertension, and pediatric oncology indications. Revenue is predominantly generated from commercial sales of proprietary prescription medicines, including Remodulin, Tyvaso, Orenitram, and Unituxin, across United States and international medical markets. United Therapeutics holds a prominent market position in pulmonary vascular disease treatment, leveraging specialized delivery systems like nebulizers and dry powder inhalers to expand patient care options. The enterprise invests substantial resources into xenotransplantation research and organ manufacturing technologies aimed at addressing critical donor organ shortages worldwide. United Therapeutics Corporation is headquartered in Silver Spring, Maryland, United States, and its common stock is publicly traded on the Nasdaq Global Select Market.
58 of the funds FundTelligence covers report a position in United Therapeutics.
- Legal name
- United Therapeutics Corp.
- Sector
- Health Care
- Country
- United States
- Funds holding it
- 58
Funds holding United Therapeutics
- Fondsfinans Global Helse — Fondsfinans · 2.31 % (full portfolio disclosed, October 2026)
- Storebrand Global Value — Storebrand · 2.04 % (full portfolio disclosed, October 2026)
- BlackRock iShares NASDAQ US Biotechnology UCITS ETF — BlackRock · 1.55 % (full portfolio disclosed, October 2026)
- Storebrand Global Multifactor — Storebrand · 1.2 % (full portfolio disclosed, October 2026)
- JPM Global Healthcare Fund — JPM · 0.67 % (full portfolio disclosed, June 2026)
- JPM Global Value Fund — JPM · 0.26 % (full portfolio disclosed, June 2026)
- Handelsbanken Global SMB Index Criteria — Handelsbanken · 0.25 % (full portfolio disclosed, October 2026)
- KLP AksjeGlobal Flerfaktor — KLP · 0.11 % (full portfolio disclosed, June 2026)
Showing the 8 largest of 58 funds holding it.